Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1819479

Next Previous
Drug Profile

BI 1819479

Alternative Names: BI-1819479

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antifibrotics
  • Mechanism of Action Lysophospholipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 16 Jan 2026 Boehringer Ingelheim completes phase-II clinical trials in Idiopathic pulmonary fibrosis in Germany, United Kingdom, Thailand, Sweden, Taiwan, Spain, South Korea, Singapore, Poland, Norway, New Zealand, Malaysia, Japan, Italy, Hungary, Greece, France, Finland, Denmark, Czech Republic, China, Canada, Brazil, Belgium, Austria, Australia, Argentina, USA (PO) (NCT06335303)
  • 08 Jan 2026 BI 1819479 receives Fast track status from the US FDA for Idiopathic pulmonary fibrosis, before January 2026 (Boehringer Ingelheim pipeline, January 2026)
  • 04 Nov 2025 Boehringer Ingelheim terminates a phase I trial in Idiopathic pulmonary fibrosis (In adults, In volunteers) in United Kingdom (PO, Tablet, Solution), due to the company's decision (NCT07065617)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top